The readiness gap

Breakthrough medical technologies rarely fail because the science is inadequate. They fail when regulatory, clinical, and operational readiness lag behind technical capability.

Readiness requires evidence that reflects procedural variability, workflows aligned with real-world practice, clear accountability for safety, and risk management that anticipates use beyond controlled development.

Clarity Surgical Advisors advises executive teams and founders at critical points, where regulatory expectations, clinical reality, and operational risk converge.

What I Advise On:

Regulatory and Evidence Strategy at Pivotal Moments

Designing claims, evidence plans, and regulatory pathways aligned with how FDA decisions are made, particularly when feedback threatens indications, labeling, or commercial positioning.

Clinical Readiness Before Broad Adoption

Structuring workflow, training, human factors, and accountability frameworks so technologies are prepared for routine surgical use, not just controlled development.

Independent Regulatory and Clinical Risk Assessment

Providing independent evaluation of regulatory positioning, evidentiary sufficiency, and postmarket exposure across surgical robotics, oncologic and ablative platforms, plastic and reconstructive surgery devices, aesthetic technologies, and infection control.

Executive Advisory at High-Consequence Decision Points

Advising executive teams and founders when regulatory, clinical, commercial, and reputational stakes converge.

Organizations Often Reach Out When:

A novel surgical or interventional technology reaches its first consequential regulatory or clinical decision, and feedback is ambiguous or threatens labeling.

Material questions about claims, evidence strategy, or pathway arise, and internal alignment begins to fracture.

Evidence plans no longer reflect real-world surgical practice or procedural variability.

Transitioning from controlled development into routine clinical use introduces new operational or safety risk.

Safety signals prompt questions about accountability, oversight, or public communication strategy.

Executive leadership seeks independent judgment grounded in regulatory and surgical experience.

Engagements may center on a single device or extend across a portfolio, applying consistent regulatory and clinical decision frameworks at critical stages of development.

“Her insights changed our regulatory strategy” Executive, MedTech firm

Discuss your next decision